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A Thrombin-Activated PAR-1 Pathway
Drives Pancreatic Ductal Adenocarcinoma
(PDAC) Growth and Metastasis
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Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer
characterized by a wide range of mutations and a dense
stromal environment that makes the disease resistant to
chemotherapy. This chemoresistance, coupled with late
stage detection, often leads to fatal prognoses for patients
diagnosed with PDAC. Little progress has been made in
improving patient outcomes over the past 40 years and there
is a need for innovative approaches to characterize molecular
pathways involved in PDAC development.
The purpose of this study is to deﬁne the role of a
transmembrane receptor, PAR-1, in PDAC malignancy,
to identify potential targets for therapeutic intervention.
Previous studies have shown that the PAR-1 pathway
is thrombin-activated, which provides a mechanism of
experimental control over its activation. An assay to
measure cell migration was used to quantify metastatic
abilities of a representative PDAC cell line, KPC2, in the

presence or absence of thrombin. The expected result was
an increase in cell migration across the membrane following
thrombin treatment, indicating increased metastatic ability.
Initial results have conﬁrmed this hypothesis and provided
evidence that the PAR-1 pathway is critical for pancreatic
tumor development and metastasis.
As this research progresses, further work will be done to
characterize downstream factors under the control of PAR1, which will contribute to the understanding of how this
pathway induces tumor progression. Furthermore, PAR-1
is a major component of the thrombosis and coagulation
pathways, and RNA sequencing data will be used to identify
cell types and factors critical to PAR-1-dependent immune
evasion.
Research advisor Stephen Konieczny writes: “Pancreatic
ductal adenocarcinoma is a lethal cancer with no
satisfactory therapeutic strategies available to patients.
Emily’s research has identiﬁed the thrombin-PAR-1
signaling pathway as critical to cell migration and cancer
metastasis, providing important new insights in developing
eﬀective therapeutics that target this deadly disease.”
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Results of the transwell migration assay measuring metastatic ability of a PDAC cell line. The thrombin treated cells show significantly
increased migration (indicated by the darker stain) when compared to the vehicle treated cells, *** p < 0.001.
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